Effect of the glucagon‐like peptide‐1 receptor agonists on diabetic peripheral neuropathy: A meta‐analysis
Shujin Fan,Yue Qiu,Jing Liu,Tianxin Zhu,Chuan Wang,Dan Liu,Li Yan,Meng Ren
DOI: https://doi.org/10.1111/jnc.16242
2024-10-27
Journal of Neurochemistry
Abstract:Diabetic peripheral neuropathy (DPN) is the most common and costly complication of diabetes, occurring in around 50% of individuals with diabetes. Common symptoms affecting 10%–30% of patients include burning, numbness, pain, and/or weakness in the distal lower extremities and progress into more extreme symptoms of neuropathic pain. Yet without figuring out effective drugs to delay or even reverse the progression of DPN. Currently, it has been found that GLP‐1 receptor agonists (GLP‐1RA) have therapeutic functions beyond lowering blood sugar, such as reducing the risk of atherosclerosis and weight loss. Some studies have also explored the ability of GLP‐1RA to treat DPN, but there is no consensus yet. This study, through systematic review and meta‐analysis, found that patients using GLP‐1RA agonists showed significant improvement in nerve conduction velocity compared to the control group and before treatment with GLP‐1RA. This suggests that GLP‐1RA may be a potentially effective drug for treating DPN. Previous researches found that glucagon‐like peptide 1 receptor agonists (GLP‐1RA) offer benefits beyond their anti‐diabetic properties, including weight loss and cardiovascular disease prevention. However, the effects of GLP‐1RA on diabetic peripheral neuropathy (DPN) remain unclear. This meta‐analysis aims to assess the potential benefits of GLP‐1RA treatment in DPN patients by evaluating peripheral neural function. Following the Cochrane Collaboration and Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines, we conducted a meta‐analysis of the clinical trials investigating the impact of GLP‐1RA treatment on peripheral neural function in patients with DPN. Outcomes were measured using electrophysiological tests, including nerve conduction velocity (NCV) and action potential amplitude. Our meta‐analysis included six studies with 271 participants. Following GLP‐1RA treatment, NCV significantly improved compared to the control group (MD 1.74; 95% CI 1.16 to 2.33; p
biochemistry & molecular biology,neurosciences